Delray Medical Center Becomes first Hospital in South Florida to Use the New Surpass Evolve Flow Diverter for Aneurysms

Delray Medical Center is the first hospital in South Florida to use the Surpass Evolve Flow Diverter for aneurysm patients.  This device is the first 64-wire cobalt chromium flow diverter designed to re-direct blood flow and promote aneurysm healing. Dr. Dennys Reyes is the first surgeon to use this technology. 

Surpass Evolve is a cutting-edge technology that is advancing the frontiers of patient care in aneurysm treatment, “said Dr. Dennys Reyes, neurointerventionalist on staff at Delray Medical Center.  “Treating at risk intracranial aneurysms before they rupture is a focus of our stroke program that can help save lives and provide some of the best care in the community.”

An aneurysm occurs when part of a blood vessel becomes weak, causing the vessel to balloon or bulge and fill with blood. Aneurysms can occur in any blood vessel in the body. However, brain aneurysms are the most life-threatening. If left untreated, the aneurysm may continue to weaken until it bursts and bleeds into the brain. Almost 500,000 deaths occur each year as a result of a brain aneurysm.  

“It has been very rewarding to see technology like this help our patients get neurological care close to home,” said Maggie Gill, chief executive officer of the Palm Beach Health Network and Delray Medical Center. “We continue to see outcomes in patients that could have been avoided if they had come to the hospital sooner and not delayed care.  We have the proper protocols in place to deliver care safely.

Delray Medical Center has the advanced technology and services to help with any neurological issues.  As a member of the Advanced Neuroscience Network, an integrated delivery system of medical professionals and hospitals focused on offering a full continuum of neurological care throughout South Florida, we focus on everything from prevention and diagnosis to treatment and rehabilitation. For more information go to our website at www.delraymedicalctr.com

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”